0|chunk|Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management

1|chunk|This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference -advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.
1	227	236 influenza	Disease	DOID_8469
1	315	325 antivirals	Chemical	CHEBI_22587
1	358	367 influenza	Disease	DOID_8469
1	DOID-CHEBI	DOID_8469	CHEBI_22587

